Boehringer Ingelheim receives European approval for Senvelgo, an oral liquid medication for diabetic cats

Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for Senvelgo (active ingredient: velagliflozin), marking a significant step for the treatment of feline diabetes in Europe. Globally, Senvelgo is the first once-daily liquid oral solution for the reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus. This breakthrough innovation will make it easier for cat owners to fit the treatment of feline diabetes into their daily lives.

Pet owners can give the once daily oral liquid solution with a small amount of food or directly into the cat’s mouth. As soon as one week after beginning treatment, Senvelgo improves the clinical signs of diabetes that cats experience by reducing elevated blood glucose levels and minimizing the risk of clinical hypoglycaemic events.4 The novel drug comes in liquid form, the formulation that cats and cat owners prefer, according to studies.  

Dr Stijn Niessen, president of the European College of Veterinary Internal Medicine (ECVIM), says, "Senvelgo will revolutionize the management of feline diabetes in Europe in a way that improves the well-being of both cats and their owners. It eases the complexity and burden of feline diabetes treatment because of the apparent lack of danger for clinical hyperglycaemia and removes the need for ongoing serial glucose monitoring. In this way, Senvelgo will help the majority of owners to efficiently control their cat’s condition, significantly improving quality of life.”

Feline diabetes mellitus is a metabolic disorder which occurs when a cat has insufficient levels of, or an abnormal response to insulin. It is one of the most common endocrine disorders in cats, and this is expected to increase due to an increasing and growing cat population. Unfortunately, nearly one out of three cats who are diagnosed with diabetes are euthanized within the first year of diagnosis, with the complexity required to treat diabetic cats often being a contributing factor.  

Eric Haaksma, head of animal health global innovation at Boehringer Ingelheim says “At Boehringer Ingelheim, our dedication lies in translating scientific progress into cutting-edge innovations for animals and their owners. The launch of Senvelgo underlines this ambition, offering a product that significantly enhances diabetic cat care and simplifies the lives of both cat owners and their feline companions.”

Following the marketing authorization in the European Union, Senvelgo will be rolled out across EU countries. Senvelgo is already approved in Switzerland, Great Britain, and the US. The company also plans to launch Senvelgo in countries around the world, pending regulatory approvals.

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!